Published by Yale News
Researchers at the Yale School of Medicine and the VA Connecticut Healthcare System have successfully tailored a personalized treatment approach for chronic pain in a severe pain syndrome known as inherited erythromelalgia.
Inherited erythromelalgia occurs when genetic mutations cause the body’s pain-sensing system to go into high gear, leading to flare-ups of pain and burning sensations in response to seemingly benign triggers, such as warm temperature and mild exercise.
The researchers applied molecular modeling and multi-electrode array technology to find the most effective drug treatment plan for two patients, guided by the exact location of the mutation in each patient’s genome. The researchers then conducted a double-blind, placebo-controlled study in which they assessed the effect of a placebo or the drug carbamazepine on the patients’ pain perception and neural activity.
The findings of the study appear in the April 18 issue of JAMA Neurology.Read the Full Article